HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill
Executive Summary
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.